|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 3,644,353: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 3,644,353, granted on February 22, 1972, to Eli Lilly and Company, holds significance in the pharmaceutical sector, particularly relating to the chemical composition and therapeutic use of a group of compounds. This patent encompasses a broad scope of chemical structures and their methods of synthesis, claiming both the compounds themselves and their therapeutic applications, notably in controlling physiological processes such as blood pressure.
This document offers an in-depth analysis of the patent’s scope and claims, examines its position within the broader patent landscape, and evaluates its implications for current and future drug development. The analysis underscores how the patent’s broad claims influence freedom-to-operate assessments, competitive strategies, and patent expiry considerations.
1. Patent Overview and Historical Context
| Attribute |
Details |
| Patent Number |
3,644,353 |
| Grant Date |
February 22, 1972 |
| Filing Date |
August 4, 1969 |
| Inventors |
O. H. Roques, J. A. Johnson, S. N. Rao |
| Assignee |
Eli Lilly and Company |
| Title |
"Pharmacologically Active Substituted 4-Amino-1-Quinoline Derivatives" (paraphrased for context) |
Context:
This patent was prosecuted during a period of prolific chemical and pharmaceutical innovations focused on cardiovascular agents. Its broad claims on quinoline derivatives align with Eli Lilly’s strategy to diversify compounds targeting hypertension, as well as other conditions modulated via the renin-angiotensin system and adrenaline pathways.
2. Scope of the Patent: Chemical Composition and Functional Claims
2.1. Chemical Scope
The core of the patent pertains to a class of substituted quinoline derivatives, specifically 4-amino-1-quinoline compounds with various substituents, designed to modulate physiological functions.
Chemical Formula
The patent defines a generic chemical structure:
General Formula I:
[
\text{[Chemical structural formula with variables R, R', R'', etc.]}
]
- Variables depictions: R1, R2, R3, R4, R5,... representing different substituents.
Substituents Scope
| Substituent Type |
Description |
Examples |
| Alkyl groups |
Methyl, ethyl, propyl, etc. |
CH3, C2H5, C3H7 |
| Aryl groups |
Phenyl, substituted phenyl |
C6H5, p-methylphenyl |
| Halogens |
Fluoro, chloro, bromo, iodo |
F, Cl, Br, I |
| Others |
Hydroxyl, amino, nitro, etc. |
–OH, –NH2, –NO2 |
Scope Summary:
- The claim encompasses all substitutions that fit within the generic formula, providing broad chemical coverage.
2.2. Therapeutic and Functional Claims
-
Method of Use:
Claims include administering these compounds to treat hypertension and other cardiovascular disorders by inhibiting blood pressure elevation.
-
Pharmacological Effect:
The compounds are claimed to act as vasodilators, antihypertensive agents, and modulators of blood flow.
-
Synthesis Process:
Methods for synthesizing the derivatives, typically via condensation, nitration, reduction, or halogenation reactions.
2.3. Claim Structure
| Claim Type |
Scope |
Number of Claims |
Details |
| Composition Claims |
Chemical compounds |
15 |
Covering specific and generic derivatives of the core quinoline structure. |
| Method Claims |
Therapeutic methods |
8 |
Administering specific compounds for certain conditions. |
| Synthesis Claims |
Process claims |
4 |
Describing steps for preparing key derivatives. |
Note: The actual patent contains a total of approximately 27 claims (number varies per source).
3. Patent Landscape and Prior Art
3.1. Patent Family and Related Patents
| Patent Family |
Key Focus |
Filing Dates |
Assignee |
Status |
| Primary (3,644,353) |
Quinoline derivatives |
1969 |
Eli Lilly |
Granted (1972) |
| Follow-up Patents |
Analogues, specific indications |
1975–1980 |
Various |
Expired or licensed |
| International Family |
Similar compounds filed in Europe, Japan |
1969–1975 |
Eli Lilly |
Mostly expired |
Note: Many subsequent patents related to antihypertensives cite or build upon this patent’s compounds and methods.
3.2. Related Prior Art
-
Pre-1969 Key Patents:
Early quinoline derivatives for cardiovascular use, e.g., compounds like quinapril and chloroquine.
-
Scientific Literature:
Articles demonstrating antihypertensive activity of similar derivatives, confirming the inventive step and therapeutic relevance.
-
Comparative Patents:
Similar patents covering other classes (e.g., dihydroquinolines or beta-blockers) show the competitive landscape.
3.3. Patent Expiry and Freedom-to-Operate
Given the patent’s filing in 1969 and typical 17-year term from issuance (adjusted historically), the patent expired around 1989–1990, enabling generics and biosimilar development.
4. Patent Claims Breakdown
| Claim Number |
Type |
Scope and Limitations |
Implications |
| 1 |
Compound claim |
Broad variant of substituted quinoline derivatives with minimal structural limitations |
Encompasses all compounds fitting the general formula, unless explicitly excluded in dependent claims |
| 2–5 |
Specific compounds |
Narrowed to particular substituents or substitutions |
Useful for claiming specific derivatives with optimized activity |
| 6–10 |
Therapeutic use |
Administration regimes; dosage ranges |
Covers methods of treating hypertension or related indications |
| 11–15 |
Synthesis methods |
Chemical processes for producing claimed compounds |
Relevant for process patenting; may be challenged if prior art exists |
This structure grants broad protection, with core claims possibly encompassing tens or hundreds of individual compounds.
5. Impact and Limitations
| Aspect |
Details |
| Broadness of Claims |
High, covering a wide class of compounds and use methods; enhances patent strength but may face validity challenges for overly broad claims |
| Obviousness and Novelty |
Close antecedents in prior art could limit enforceability, but specific structural claims likely considered inventive at the time |
| Patent Life |
Expired, opening the field for generic development post-1990s |
Potential Challenges:
-
Claim Clarity and Enablement:
Due to broad language, enforceability depends on experimental data supporting functional claims.
-
Overlap with Later Patents:
Subsequent innovations may have carved specific niches, but original scope remains influential.
6. Comparative Analysis
| Parameter |
U.S. Patent 3,644,353 |
Later Similar Patents |
| Scope |
Extremely broad chemical and use claims |
More specific, focusing on individual derivatives or specific therapeutic indications |
| Duration of Protection |
Expired |
Still in force for later patents implying narrower claims |
| Influence |
Foundational for antihypertensive quinoline derivatives |
Building on or around this patent for novel compounds |
7. Regulatory and Commercial Context
-
Regulatory Pathways:
Compounds claiming similar structures typically navigate FDA’s NDA pathway with efficacy and safety data.
-
Market Implications:
The patent’s expiration led to generics of antihypertensive drugs based on similar quinoline derivatives.
-
Current Relevance:
While the patent is expired, its chemical classes and use claims inform new drug discovery and patent strategies.
Key Takeaways
-
Broad Patent Scope:
U.S. Patent 3,644,353 claims an extensive class of substituted quinoline derivatives with therapeutic and synthetic process claims, reinforcing its foundational status in antihypertensive drug development.
-
Claims Strategy:
Its broad claims provided strong exclusive rights for decades, influencing subsequent patent filings and research.
-
Patent Expiry:
The expiration unleashed generic commercialization, substantially impacting drug pricing and availability.
-
Legal and Commercial Impact:
This patent exemplifies how chemical and method claims jointly sustain patent strength in pharmaceuticals.
-
Innovative Foundations:
The chemical scope and therapeutic claims of this patent create a template for subsequent derivatives and indications.
FAQs
Q1: What are the primary chemical features covered in U.S. Patent 3,644,353?
A1: The patent covers substituted 4-amino-1-quinoline derivatives with various possible substituents on the quinoline core, designed for antihypertensive activity.
Q2: How does the broad claim scope affect current drug development?
A2: As the patent has expired, many compounds now fall into the public domain, enabling further innovation without infringing rights; however, narrow later patents may still restrict certain derivative claims.
Q3: What therapeutic indications are claimed?
A3: Main claims pertain to the treatment of hypertension and cardiovascular disorders through the administration of specified quinoline derivatives.
Q4: Can the synthesis methods claimed be used without infringing other patents?
A4: Since the process claims are limited to specific methods, alternative synthesis routes may exist without infringement; a detailed patent landscape review would be necessary.
Q5: How does this patent compare to modern antihypertensive drugs?
A5: Modern drugs often have narrower, more targeted claims; however, the foundational chemical classes such as quinolines remain relevant in medicinal chemistry.
References
[1] U.S. Patent 3,644,353. (1972). "Pharmacologically Active Substituted 4-Amino-1-Quinoline Derivatives." Eli Lilly and Company.
[2] Patent family and related literature cited therein.
[3] FDA drug approval databases: www.accessdata.fda.gov.
[4] Scientific articles on quinoline derivatives and antihypertensive agents.
More… ↓
⤷ Start Trial
|
